Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Today’s mass-produced tomatoes often grow to palm-sized proportions, but their naturally occurring ancestors were far smaller ...

Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...

CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...

Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...

They realized that if they “release” these breaks, tomatoes could become much sweeter. They used CRISPR-Cas9 gene-editing ...

A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...